161 First Street
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those directly impacted by the disease, Solid aims to be the center of excellence across the entire DMD disease spectrum, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease Modifying Therapies, Disease Understanding and Assistive Devices.
Founder and CEO: Ilan Ganot
Founder, Patient Advocacy: Annie Ganot
CMO: Jorge A. Quiroz, M.D.
SVP Operations: Alvaro Amorrortu
Please click here for Solid Biosciences' technology.
26 articles with Solid Biosciences
Although a definite blow to Sarepta, this may have negative implications for other companies working to develop therapies for DMD. This includes Wave Life Sciences and Solid Biosciences.
Here's a roundup of some of the top clinical trial news from the previous week.
In its first-quarter financial report, Solid Biosciences updated on its Phase I/II IGNITE DMD clinical trial. The progress was marred by adverse events.
Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy
Solid Biosciences (Nasdaq:SLDB) announced today preliminary findings from IGNITE DMD, the Company's Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression.
Shares of Solid Biosciences have plunged more than 71 percent after the company revealed early data from a Phase I/II trial that showed low doses of its gene therapy treatment may lack the potential to be as effective a treatment for Duchenne muscular dystrophy as current products on the market.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Most of the IPOs that occurred in the Bay State have been well-documented by BioSpace. But, with a new calendar year upon us, it’s a good idea to look back at a banner year of capitalization that may not repeat when January rolls around. With the turn of the year only days away, BioSpace takes a ...
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
Shares of Solid Biosciences have jumped 11 percent in premarket trading after the company announced the U.S. Food and Drug Administration has lifted a clinical hold on the company’s Phase I/II clinical trial gene therapy treatment for Duchenne muscular dystrophy (DMD).
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
WeissLaw LLP announced that a class action was filed in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired shares of Solid Biosciences Inc.
SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc.
SOLID BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc.
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Solid Biosciences Inc. (SLDB) and Lead Plaintiff Deadline: May 28, 2018
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Solid Biosciences Inc. ("Solid" or the "Company") (NASDAQ: SLDB) and certain of its officers, on behalf of shareholders who purchased Solid securities (1) in Solid's initial public offering on or about January 25, 2018; or (2) on the open market from January 25, 2018 through March 14, 2018, inclusive (the "Class Period").
Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Solid Biosciences Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB) or certain of its officers and directors violated federal securities laws.
A U.S. Food and Drug Administration announced their decision to slap a clinical hold on Solid Biosciences Inc.’s experimental gene therapy treatment for Duchenne muscular dystrophy.
Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option
J.P. Morgan, Goldman Sachs & Co. LLC and Leerink Partners acted as joint book-running managers of the offering,
The surprising disclosure was outlined in a November 2017 letter from the FDA.
Three biotech companies want to start out the new year with a new start.